CA Stem Cell Agency Lauds Multibillion-Dollar ’47’ Deal
March 9, 2020
(Capitol Weekly) – Forty Seven, Inc., was gobbled up last week for $4.9 billion by its neighbor, Gilead Sciences, Inc., in Foster City. The figure represents a 1,600 percent increase in Forty Seven’s stock price since last October.
“To say this is incredible would be an understatement!” said Maria Millan, president and CEO of the California Institute for Regenerative Medicine (CIRM), as the stem cell agency is formally known. She had good reason for her enthusiasm.